Effects of ROSIglitazone on inflammatory markers and adipokines in diabetic patients using an angiotensin receptor blocker (TELmisartan) - the ROSITEL study.
Phase of Trial: Clinical Phase Unknown
Latest Information Update: 12 Feb 2016
At a glance
- Drugs Metformin; Rosiglitazone; Sulfonylureas
- Indications Type 2 diabetes mellitus
- Focus Pharmacodynamics
- Acronyms ROSITEL
- 10 Jun 2017 Biomarkers information updated
- 24 Nov 2010 Actual end date (Jun 2009) added as reported by ClinicalTrials.gov.
- 24 Nov 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.